I am a
Home I AM A Search Login

Papers of the Week

Papers: 7 Jan 2023 - 13 Jan 2023

Human Studies

2022 Dec 23

J Clin Med



Treatment of Primary Nummular Headache: A Series of 183 Patients from the NUMITOR Study.


García-Iglesias C, Puledda F, Echavarría-Íñiguez A, González-Osorio Y, Sierra-Mencía Á, Recio-García A, González-Celestino A, Valle-Peñacoba G, Irimia P, Guerrero-Peral Á L, García-Azorín D
J Clin Med. 2022 Dec 23; 12(1).
PMID: 36614923.


Nummular headache (NH) is a primary headache characterized by superficial coin-shaped pain. NUMITOR (NCT05475769) is an observational study evaluating the responder rate of preventive drugs in NH patients. The treatment response was assessed between weeks 8 and 12 compared with the baseline. Patients were included between February 2002 and October 2022. Demographic and clinical variables were assessed; treatment response was estimated by 50%, 30%, and 75% responder rates and treatment discontinuation due to inadequate tolerability. A total of 183 out of 282 patients fulfilled eligibility criteria and completed the study. Patients were aged 49.5 (standard deviation (SD): 16.8) years, and 60.7% were female. NH phenotype was a parietal circular pain of four centimeters' diameter, moderate intensity, and oppressive quality. At baseline, patients had 25 (interquartile range) pain days per month. Preventive treatment was used by 114 (62.3%) patients. The highest 50% and 75% responder rates corresponded to onabotulinumtoxinA (62.5%, 47.5%), followed by gabapentin (43.7%, 35.2%). Oral preventive drugs were not tolerated by 12.9-25%. The present study provides class IV evidence of the effectiveness of oral preventive drugs and onabotulinumtoxinA in the treatment of primary NH. OnabotulinumtoxinA was the most effective and best-tolerated drug, positioning it as first-line treatment of NH.